Abstract: Oral anticoagulant therapy (OAT) calls for continuous control by prothrombin time (PT) test, as the therapeutic range in INR units is very narrow. Warfarin (or coumarin) inhibits coagulation factor synthesis in the liver, but at the same time inactive coagulation factors are formed. The aim here was to measure "active coagulation factors" and inhibition in calibrator kits and patient plasmas by a new method for Quick and Owren PT.
INTRODUCTION
The prothrombin time (PT) test is used mainly to control oral anticoagulant therapy (OAT). PT is the most widely used coagulation test in clinical laboratories and in year 2000 about 800 million tests are carried out globally. The number of tests is increasing about 10 % a year. OAT is based on the ability of warfarin as a vitamin K antagonist, to slow down the synthesis of active coagulation factors in the liver (F II, F VII, F IX and F X). Warfarin medication requires continuous monitoring to prevent the serious consequences of thrombosis or bleeding, which may mean patient death [1] . Mortality has been seen to be strongly related to the level of the International Normalized Ratio (INR), and accuracy in patient care is very important.
The prothrombin time is commonly measured by either the "Quick PT", which is based on the technique described by Quick and co-workers in 1935 [2, 3] or by the "Owren PT" [4] (combined thromboplastin reagent). The latter is the predominant approach used in the Nordic countries, Benelux, and Japan, both methods being nevertheless suitable for the control of anticoagulant treatment. The WHO recommendation for the use of INR aims to harmonize PT results for OAT regardless of the reagent, instrument or method used [5, 6] .
Though expectations of harmonization of results using INR are not fulfilled in routine measurements [7] [8] [9] [10] [11] [12] [13] , the therapeutic ranges are globally the same as those of INR for different clinical indications.
The editorials of Clinical Chemistry have posed the critical question and sought answers: "Has the Time Arrived to Replace the Quick Prothrombin Time Test for Monitoring Oral Anticoagulant Therapy ?" [7] . Horsti compared the Quick and Owren PT methods for harmonization of INR results and concluded that Quick PT yields clinically divergent and Owren PT clinically acceptable INR results [12] . Lindahl and colleaques noted that the current International Sensitivity Index (ISI) calibration standardization procedure is complex and recommend normal plasma calibration with dilutions [14] . Horsti and associates in a recent study presented "A new-generation prothrombin time method", which measures active coagulation factors F II, F VII, F X and separately the inhibition caused by inactive coagulation factors F II, F VII, F X , which totally or partly lack gamma carboxyglutamic acid for factor activation [15] [16] [17] [18] . This study by Owren PT found that OAT patients should be medicated using INR from active coagulation factors and calibrators should not contain inhibitors.
The aim of this present study was to establish whether "The New-generation PT method" is appropriate for Quick PT and whether we can harmonize INR results between Owren and Quick PT's, and to what extent ISI calibrators contain inactive coagulation factors for Quick PT.
MATERIALS AND METHODOLOGY

Patients and Blood Sampling
Venous blood samples were obtained from 10 normal subjects and 210 hospital and health-centre patients for whom the PT time test was requested for the monitoring of oral anticoagulant therapy. In our region a "P-INR" test code is used for this purpose. The patient samples thus represented all possible phases of anticoagulation: (i) pre-treatment, (ii) dose-adjusting phase, and (iii) steady-state phase. All procedures were approved by our institution's responsible committee in accordance with the Helsinki Declaration of 1975. Blood (1.8 mL) was drawn into citrate coagulation tubes (Greiner Labortechnik GmbH, Vacuette cat. no. 454322, 9NC) containing 0.2 mL 0.109 mol/L (3.2 %) citrate solution. The sample needle (Terumo, Venoject needle, Quick Fit, cat. no. MN-2138MQ) was 0.8 x 40 mm. Sample tubes were centrifuged at 1850 g for 10 min at 20 o C to separate plasma. All measurements were commenced within 8 hours of blood collection.
PT Determination
The PT coagulation times were measured using a fully automated BCS coagulation analyser (DadeBehring Coagulation System, DadeBehring, Marburg, Germany).
For the one-stage propthrombin time with Quick PT, 100 L of coagulation reagent was added to 50 L of citrated plasma and for dilution the sample volumes were 100 L +25 L + 25 L(a physiologic salt solution, Natriumklorid 9 mg/mL, 500ml from Kabi). The reagent was Dade Innovin cat. no. B4212-50 (recombinant human tissue thromboplastin, DadeBehring Marburg GmbH), lot 536928, ISI for BCS 0.92.
Owren PT method (combined thromboplastin reagent): the coagulation reactionmixture contained 10 L of citrated sample plasma, 60 L of diluent and 140 L of reagent for normal PT measurement and 5 l of citrated sample plasma, 65 L of diluent and 140 L of reagent for patient and calibrator measurements using the new PT method.
The reagent was Nycotest PT, cat. no. 1002488 (rabbit brain thromboplastin) and a diluent (Nycotest PT, dilution liquid, cat.no. 1002485) from Axis-Shield as, lot 10112954, ISI=1.07.
ISI Calibration
Two local ISI calibrator kits were used: (i) "Svensk nationell kalibrator för protrombinkomplexaktiviet", from Equalis, lot 11, 12 
Determination of Minimal PT Time and Respective INR
The construction of a PT sec (y axis) versus C (where C is the dilution factor of normal plasma, OAT plasma, or calibrator) plot shows, at the intercept of the line obtained from the experiment, the so-called minimal clotting time (t min ). The inhibition effect can be calculated from the differences in intercepts of the unknown sample and normal plasma (or INR "zero" calibrator). In practice, only two dilutions are required for each determination [15] .
The inhibition principle on the y axis is illustrated in Fig.  1 A and B 
Analytical Imprecision and Statistics
The within-run precision of PT tests was measured using one patient plasma sample (n = 10 determinations) with an INR value in the therapeutic range, i.e., approx. 2.2 INR. The respective CVs were: 2.6 % for Dade Innovin and 1.6 % for Nycotest PT. This is consistent with our previous observations with a broader spectrum of reagents [13] . The Microsoft Excel 5.0 program was used to obtain the correlation functions and INR results.
RESULTS
Inhibition in INR units and percentages using the Quick and Owren PT on four commercial calibrator kits is presented in Table 1 and Fig. (1) .
The inhibition is dependent on thromboplastin sensitivity and the PT method used. (Fig. 2) 
DISCUSSION
For a number of years new medications for anticoagulation therapy have been presented and anticipated without laboratory test control in an attempt to displace warfarin medication. The new medicines have proved inappropriate either in being too expensive or having serious side-effects. Since warfarin is a very cheap medicine it would be impor- Calibrator sets tant to develop therapy with more attention to patient care in this competition.
The INR system transferred the responsibility to global laboratories to produce "the same INR from the same sample". This is a formidable challenge in view of different methods, reagents and instruments requiring harmonization. The current WHO calibration recommendation is complex [14] and calibration itself involves errors. We encountered this problem in our earlier study, where the same calibrator kit was used for seven different reagents [13] .
In this present study we observed marked differences between calibrator kits in respect of inactive coagulation factors. The Quick PT is more sensitive to inhibition than the Owren and requires more calibrators and more correction at different INR levels. Different methods, thromboplastins and reagents have variable sensitivity to inactive coagulation factors and call for correction of inhibition or use of normal plasma. It is a cardinal error for calibration to contain inhibitory coagulation factors and hence the only possibility is to use normal-plasma dilution calibration.
An alternative means of determining the International Sensitivity Index is the use of freshly pooled plasmas from 20 normal individuals and 60 patients on OAT. These numbers of samples are necessary to obtain a precise calibration line for ISI calculation [19] . In this model the inhibition is constant or average at 2.5 INR. Current calibration involves average inhibition correction, which does not guarantee good INR result hamonization for individual patient sample.
The 200 OAT patient samples analysed show that the Quick PT needs more correction than the Owren to measure active coagulation factors (INR Acf ). Inactive coagulation factors have more effect on Quick than on Owren PT, an observation which explains why using the same calibration for Quick PT reagents it is more difficult to harmonize INR than for Owren PT [12] . In our earlier study can we notice good harmony at INR 1 which get worse at higher INR values for seven different reagents [13] . This proves that the inhibition and disharmony increase together towards higher INR values. Inhibition correction for INR harmonizes the Quick and Owren PT methods very well through the measuring range. More accurate INR results mean better control for warfarin therapy and improved patient safety and possible less need for laboratory controls. The new method requires two measurements and a simple mathematical calculation for one patient sample. The current PT methods measure the sum of active coagulation factors and inhibition of inactive coagulation factors. 
